Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC; warrants: TDACW) is a blank-check company formed to pursue an acquisition target in the life sciences and biotechnology sector, with a specific emphasis on translational medicine and development-stage healthcare companies. The company filed an 8-K current report with the SEC on December 27, 2024, accession number 0001104659-24-132134, reflecting continued activity in its SPAC lifecycle. TDAC is part of a cohort of life sciences-focused special purpose acquisition companies that emerged during the active SPAC issuance period of the early 2020s. For full sponsor details, deal timeline, SEC filing history, and real-time status data on TDAC, sign up for SpacDesk.